RESTORE | Using Rivaroxaban to Prevent Radial Artery Occlusion After an Intervention

Radial access has long demonstrated its benefit, but one of its most feared complications is radial artery occlusion (RAO), which can vary from 1% to 5% according to different series.

Uso de Rivaroxaban para prevenir oclusión de arteria radial posterior a una intervención

There is currently no significant information on post-procedural anticoagulation and the presence of RAO at follow-up.

The aim of the randomized RESTORE study was to examine the effect of post-intervention anticoagulation with rivaroxaban to reduce radial artery occlusion at 24 hours and at 1 month.

The primary endpoint (PEP) was the incidence of RAO within 24 h (early RAO). The secondary endpoint (SEP) was the incidence of RAO at 1 month (late RAO) and bleeding episodes.

The study included 382 patients; half of them were randomized to the control group and the other half, to the rivaroxaban group (10 mg daily for 7 days). Mean patient age was 64 years old. Most patients were men, presenting hypertension and dyslipidemia as the most frequent risk factors. Fifty percent of their procedures were therapeutic/IVUS (intravascular ultrasound).

There were no significant differences between groups in terms of the PEP. However, for the SEP there was a difference in favor of the rivaroxaban group (p = 0.011), with no higher bleeding rate.

Read also: Is iFR Reliable After 5 Years? Analyzing the iFR-SWEDEHEART at 5 Years.

In the subgroup analysis, a lower incidence of early RAO was observed in the rivaroxaban group in female patients and in diabetic patients.

Conclusion

Short-term use of rivaroxaban after the procedure did not affect the incidence of RAO within 24 hours, but reduced occlusion after a 1-month follow-up. More studies are warranted to evaluate this efficacy.

Dr. Andrés Rodríguez
Member of the editorial board in SOLACI.org.

Original Title: Short-Term Postoperative Use of Rivaroxaban to Prevent Radial Artery Occlusion After Transradial Coronary Procedure: The RESTORE Randomized Trial.

Reference: Dongjie Liang et al Circ Cardiovasc Interv. 2022;15:e011555.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

Transcatheter Pulmonary Valve Implantation with a Self-Expanding Valve: Outcomes at 3 Years

Pulmonary regurgitation (PR) is a common condition in patients who have undergone surgical repair of Tetralogy of Fallot or other pathologies involving the right...

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...